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Objectif: nous avons regardé si les sujets dont les parents vivaient plus longtemps 
présentaient des niveaux plus faibles de facteurs de risques cardiovasculaires, y compris pour 
le syndrome métabolique. 
Méthodes: nous avons analysé les données d'un échantillon représentatif de la population 
suisse (1163 hommes et 1398 femmes) âgé de 55 à 75 ans, de la ville de Lausanne. Les 
participants ont été stratifiés par nombre de parents (0, 1, 2) qui ont vécu jusqu'à 85 ans ou 
plus. Les associations entre la longévité parentale et les facteurs de risques cardiovasculaires 
ou les variables métaboliques associées ont été analysées au moyen de régressions linéaires 
multiples. 
Résultats: la prévalence ajustée pour l'âge du syndrome métabolique varie de 24.8%, 20.5% 
à 13.8% chez les femmes (P<0.05) et de 28.8%, 32.1%à27.6% chez les hommes (non 
significatif) pour 0, 1 et 2 parents à forte longévité. L'association entre la longévité parentale 
et la prévalence du syndrome métabolique est particulièrement forte pour les femmes qui 
n'ont jamais fumé. Dans ce groupe, les femmes qui ont 2 parents à forte longévité ont un BMI 
plus faible et un tour de taille moins grand. Chez les gens qui n'ont jamais fumé, pour les 
deux sexes, les niveaux moyens (95% d'intervalle de confiance) et ajustés de cholestérol-
HDL étaient de 1.64(1.61-1.67), 1.67(1.65-1.70) et 1.71(1.65-1.76) mmol/L pour 0, 1et2 
parents à forte longévité (P<0.01), respectivement. La tendance n'était pas significative chez 
les anciens fumeurs et fumeurs actuels. 
Conclusions: la longévité parentale est associée à un meilleur profil métabolique chez les 
femmes, mais pas chez les hommes. Les avantages métaboliques du fait d'avoir des parents 
âgés sont fortement atténués par le tabagisme. 
Mots clés: vieillissement; maladie cardiovasculaire; obésité; épidémiologie 
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ABSTRACT 
Objective: We evaluated whether subjects with long-lived parents show lower levels of 
cardiovascular risk factors, including the metabolic syndrome. 
Methods: We analyzed data from a Swiss population-based sample (1163 men and 1398 
women) aged 55-75 years from Lausanne. Participants were stratified by number of parents 
(0, 1, 2) who survived to 85 years or more. The associations of parental longevity with 
cardiovascular risk factors and related metabolic variables were analyzed using multiple 
linear regressions. 
Results: Age-adjusted metabolic syndrome prevalence varied from 24.8%, 20.5% to 13.8% 
in women (P<0.05) and from 28.8%, 32. l % to 27.6% in men (not significant) with 0, 1 and 2 
long-lived parents. The association between parental longevity and metabolic syndrome 
prevalence was particularly strong in women who had never smoked. In this group, women 
with 2 long-lived parents had lower BMI and smaller waist circumference. In never-smokers 
ofboth genders, mean (95% CI) adjusted HDL-cholesterol levels were 1.64(1.61-1.67), 
1.67(1.65-1.70) and 1.71(1.65-1.76) mmol/L for 0, 1and2 long-lived parents (P<0.01), 
respectively. The trend was not significant in former and current smokers. 
Conclusions: In women, not in men, parental longevity is associated with a better metabolic 
profile. The metabolic benefits of having long-lived parents are offset by smoking. 
Keywords: aging; cardiovascular disease; obesity; epidemiology 
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INTRODUCTION 
Longevity aggregates in families, and parents who live longer generally have offspring with 
longer life expectancy (Atzmon et al. 2004; Martin et al. 2007; Perls et al. 2002; Terry et al. 
2007). In mortality studies, increased longevity has been mainly attributable to reduced 
cardiovascular mortality (Ikeda et al. 2006; Menotti et al. 2006; Rosengren et al. 2002). It has 
therefore been hypothesized that longevity results from reduced susceptibility to 
cardiovascular disease (Terry et al. 2004; Tunstall-Pedoe et al. 1999). 
Parental longevity has been associated with a favorable cardiovascular risk profile in several 
studies (Barzilai et al. 2001; Hammond et al. 1971; Reed et al. 2003; Terry et al. 2003; Terry 
et al. 2004; Terry et al. 2007; Yarnell et al. 2003; Zureik et al. 2005). In the Framingham 
Offspring study (Terry et al. 2007), offspring with long-lived parents had a more favorable 
cardiovascular risk profile with lower increase in blood pressure and Framingham risk score 
during follow-up compared to offspring whose parents <lied at a younger age. To our 
knowledge, there is little information on the biological profile of offspring of long-lived 
parents and on the effect of additional cardiovascular and metabolic markers such as insulin, 
adiponectin, leptin and homocystein, and inflammation markers such as ultrasensitive C-
reactive protein (CRP) and uric acid. 
In an effort to expand our understanding of the effect of parental longevity on cardiovascular 
diseases, we performed detailed analyses of the relationship between parental longevity and a 
large array of metabolic variables in the population-based Co Laus Study in Lausanne, 
Switzerland, a resource which has already been used to examine the phenotypic and genetic 
determinants ofvarious traits (Firmann et al. 2008; Marques-Vidal et al. 2007; Marques-
Vidal et al. 2008; Rodondi et al. 2008; Sandhu et al. 2008). We restricted these analyses to 
subjects aged 55 or more to avoid left-censoring of parental longevity information (i.e. 
parents of young subjects are more likely to be alive and their longevity is therefore 
unknown). 
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METHODS 
Study population 
The study was approved by the Ethics Committee of the Faculty of Medicine of Lausanne. 
Recruitment began in June 2003 and ended in May 2006 (Firmann et al. 2008). The complete 
list of Lausanne inhabitants aged 35-75 years (n=56,694) was provided by the population 
registry of the city. A simple non-stratified random sample of 35% of the overall population 
was drawn. Inclusion criteria were: a) written informed consent; b) age between 35 and 74 
years; c) willingness to donate data, blood and urine samples and d) Caucasian descent. Out 
of the 6188 participants, we excluded 3509 subjects who were younger than 55 years. In 
addition, we excluded 108 subjects due to missing data on parental longevity and 10 for 
missing covariates, so that 2561 subjects were included in the present analysis. In this group, 
1298 individuals had neither parent alive or had both their parents deceased before they 
reached 85 years, 991 individuals had one parent alive or one parent deceased after 85, and 
272 had both parents either still alive or deceased after the age of 85. 
Questionnaire data 
Trained health professionals used a standardized questionnaire on socio-demographic 
characteristics and family history. The following questions were asked: "Is your father still 
alive?"; "If yes, how old is he?" ; "If no, at what age did he die?" The same questions were 
asked about the mother of each participant. 
Assessment process and data collection 
Participants attended the outpatient clinic of the University Hospital Center of Lausanne 
(CHUV) in the morning after an overnight fast. For the purpose of this analysis, smoking was 
defined as present if a participant reported to be a current smoker at the time of examination, 
alcohol consumption was defined as present for participants who reported drinking alcohol at 
least once a day. 
Body mass index (BMI) was defined as weight in kg divided by height in meters squared. 
Waist was measured over the unclothed abdomen at the narrowest point between the lowest 
rib and the iliac crest. Blood pressure and heart rate were measured three times on the left 
arm after at least a 10 minute rest in the seated position, using a clinically validated automatic 
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oscillometric device (Omron HEM-907, Matsusaka, Japan)(El Assaad et al. 2002), with an 
appropriately sized cuff. The average of the second and third readings was used for analyses. 
Hypertension was defined as a mean systolic blood pressure (SBP) ~ 140 mm Hg and/or a 
diastolic blood pressure (DBP) ~ 90 mm Hg and/or presence of antihypertensive drug 
treatment. 
A venous blood sample was collected in each participant under fasting conditions (8 hours 
requested). Blood tubes were centrifuged at 1,500 rpm for 10 minutes at 4°C within 2h. of 
admission. The CHUV Clinical Laboratory, which is ISO 9001 certified and regularly 
checked by the Swiss Centre for Quality Control, conducted all measurements in a Modular P 
apparatus (Roche Diagnostics, Switzerland). The analytical procedures for biological markers 
and clinical chemistry methods have been described previously (Firmann et al. 2008). 
Diabetes was defined as a fasting blood glucose 2: 7 mmol/l and/or presence of any 
antidiabetic drug (including insulin). Hypercholesterolemia was defined as a fasting blood 
cholesterol 2: 6.2 mmol/l and/or presence of lipid lowering drugs. 
Statistical analyses 
Statistical analyses were performed using Stata 9.2 (Stata Corp, College Station, USA). 
Quantitative data were expressed as means ±standard deviations. Qualitative data were 
expressed as number of subjects and percentage. Participants were stratified by the number of 
parents who survived to age 85 or more as follows: 0 parent alive, 1 parent alive, or both 
parents alive at age 85 or more. We chose a eut-off of 85 years because this is the commonly 
accepted definition of the oldest old (Suzman et al. 1985). 
We first conducted simple linear regression across the three categories of parental longevity, 
coded as 0, 1 and 2 for the number of parents alive or dead at age 85 or older. We compared 
these unadjusted results with (1) full models not adjusted for BMI, (2) full models adjusted 
for BMI. Full models included age, sex, alcohol ( coded as 1 if at least one standard drink a 
day and 0 otherwise), tobacco consumption and educational level (as a proxy for 
socioeconomic status). For blood pressure, further adjustment was made for antihypertensive 
treatment; for lipid markers, further adjustment was made for lipid-lowering treatment. For 
height, full adjustment included weight instead of BMI; for weight, full adjustment included 
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height instead of BMI; for waist, full adjustment included BMI. We tested all models for an 
interaction of parental longevity with the participant's sex. Results were stratified by sex 
whenever this interaction was significant. We also compared the effects of parental longevity 
in former or current smokers versus never smokers. 
We calculated ten-year coronary heart disease (CHD) risk score using the Framingham risk 
fonction (Wilson et al. 1998) and compared trend across the three parental categories of 
parental longevity using a non-parametric test for trend as implemented in the Stata nptrend 
fonction. The presence of metabolic syndrome was defined using the Adult Treatment Panel 
III definition of the National Cholesterol Education Pro gram (Adult Treatment Panel III 
2002), and trends across categories of parental longevity were assessed in a similar way. Age-
adjusted prevalence was calculated using the direct standardization method (proportion 
fonction) in Stata. 
RESULTS 
Participants' characteristics 
Participants' characteristics are listed in Table 1. Women had lower BMI, weight and height, 
lower education levels and prevalence of alcohol and tobacco consumption than men. 
Associations of parental longevity with anthropometric variables 
BMI was much lower in women with longer-lived parents than in other women (Table 2). 
This was attributable to both lower weight and higher height. The weight difference between 
women with 2 and 0 long-lived parents was 3.8 kg. Women with longer-lived parents had 
lower waist circumference, even after adjusting for BMI. Similar non significant trends were 
found in men. 
In female never smokers, a significant trend was observed towards lower BMI, weight and 
waist circumference with increasing parental longevity (Figure 1). Similar trends, but only of 
borderline significance, were found in female former and current smokers. No such trends 
were observed in men, regardless of smoking status (Figure 1). 
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Associations of parental longevity with cardiovascular risk factors 
For most variables analyzed (Table 3), we observed trends towards lower cardiovascular risk 
profile as parental longevity increased. With the exception of pulse pressure, these trends 
were not significant after adjustment for BMI. The fact that adjustment for BMI attenuated 
these trends suggests that the lower cardiovascular risk profile associated with parental 
longevity is mediated, in part, by BMI. We found no significant interaction of parental 
longevity with sex for these variables. In never smokers (supplementary table 3a), fully 
adjusted (including BMI) means (95% CI) for HDL-cholesterol levels were 1.64 ( 1.61-1.67), 
1.67 (1.65-1.70) and 1.71 (l.65-1.76) mmol/L for 0, 1 and 2 long-lived parents, respectively 
(p < 0.01). The corresponding means were 1.56 (1.54-1.59), 1.57 (1.55-1.59) and 1.58 (l.54-
1.62) in the group of former and current smokers (p > 0.05) (supplementary table 3b). 
We conducted similar analyses with other selected variables: the results are summarized in 
Table 4. CRP, liver enzymes, leptin and uric acid all showed significant trends across 
categories of parental longevity, but only AST remained significant after adjustment for BMI. 
All these variables showed a trend towards better health condition with longer parental 
longevity. Analyses stratified by smoking status are available in supplementary table 4a and 
4b. 
Table 5 shows how the Framingham Risk Score evolves through each category of parental 
longevity. A significant trend towards better cardiovascular profile was observed in women 
whose parents lived the longest. These results confirmed what we obtained for separate 
cardiovascular risk factors. We found a lower Framingham Risk Score among female never 
smokers with long-lived parents, but not among former or current smokers. 
Associations of parental longevity with the metabolic syndrome 
Women, but not men, with longer-lived parents had lower age-adjusted prevalence of the 
metabolic syndrome (Figure 2). In women, the age-adjusted prevalence of the metabolic 
syndrome varied from 24.8%, 20.5% to 13 .8% for 0, 1 and 2 long-lived parents, respectively, 
whereas in men the corresponding values were 28.8%, 32.1 % and 27.6%. When stratifying 
by smoking status, female never smokers showed a strong and significant trend for lower 
prevalence in metabolic syndrome with increasing parental longevity. Female former or 
current smokers and men didn't show such a trend (Figure 2). These results suggest that, in 
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women, the beneficial effects of parental longevity on the metabolic syndrome are offset by 
smoking. 
DISCUSSION 
We found that increased parental longevity was strongly associated with decreased 
prevalence of the metabolic syndrome in women, but not in men. To our knowledge, this is 
the first time that this association has been reported. In women, the prevalence of the 
metabolic syndrome decreased from 24.8% to 13.8% across categories of increasing parental 
longevity. The size of this effect is remarkable considering that parental longevity was only 
reported, and not observed. These findings outline the power of family history to capture 
increased susceptibility to the clustering of cardiovascular risk factors. Our results are 
consistent with previous studies showing that longevity is associated with reduced 
cardiovascular mortality (Ikeda et al. 2006; Menotti et al. 2006; Rosengren et al. 2002). We 
provide an additional dimension to this picture by showing that this lower cardiovascular 
mortality is partly mediated by the clustering of risks as observed in the metabolic syndrome. 
Gender differences in cardiovascular morbidity and mortality are well known (Muller-
N ordhorn et al. 2008). In this study, an inverse association between parental longevity and 
prevalence of the metabolic syndrome was observed in women, but not in men. Similarly, the 
inverse association between Framingham Risk Score and parental longevity was only 
observed in women. This may reflect the fact that women are fitter than men. Following this 
perspective, environmental or genetic determinants of increased longevity might show their 
effects more clearly in subjects who are healthier. We cannot exclude that part of the 
observed sex differences are explained by the fact that daughters give more accurate 
information than sons regarding their parental longevity. However, in the field of cardiovascular 
risk factors, several studies showed no clear difference in the validity of family history between men 
and women (Bensen et al. 1999; Karter et al. 1999; Murabito et al. 2004). Compared to men, the 
conjunction of lower BMI, lower prevalence of metabolic syndrome, and lower Framingham 
Risk Score in women may explain why the heredity of longevity was greater among women 
than men. Our results suggest that all cardiovascular risk factors need to be low for the 
heredity of longevity to become apparent. The fact that male gender itself may be seen as a 
cardiovascular risk factor could explain why we observed no association between parental 
longevity and cardiovascular clustering in men. 
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Strong, further evidence to back up this hypothesis is that the association between parental 
longevity and cardiovascular risk varied according to smoking status. First, increased parental 
longevity was associated with lower prevalence of the metabolic syndrome mainly in women 
who had never smoked. Furthermore, the association of increased parental longevity with 
lower weight, BMI and waist, and with higher HDL-cholesterol levels was much stronger in 
female never smokers than in female former or current smokers. Smoking, through its 
gerontogenic effects (Bernhard et al. 2007; Martin 2000), could reduce or neutralize the 
beneficial effect of increased parental longevity on the cardiovascular risk profile. This could 
also be the case for other acquired risk factors. 
Our results underline the importance of BMI as a link between parental longevity and 
cardiovascular risk factors. Before adjusting for BMI, increased parental longevity was 
significantly associated with lower levels of several cardiovascular risk factors. Several 
associations (i.e., with systolic blood pressure, HDL-cholesterol and triglycerides) were 
attenuated after correcting for BMI. Moreover, the association of increased parental longevity 
with lower levels of inflammation markers ( e.g., lower CRP) disappeared after correcting for 
BMI. Hence, the lower cardiovascular risk observed in offspring of long-lived parents could 
be partially mediated by lower BMI. Our findings are consistent with the association of 
obesity with cardiovascular risk factors clustering (Grundy 2007). Our findings are also 
consistent with the observation that obesity is a cardiovascular risk factor in primary 
prevention settings (i.e. very low prevalence of cardiovascular disease in our sample)(Yusuf 
et al. 2004). Since BMI results from genetic as well as non-genetic determinants, it may not 
only act as a mediator but also as a confounding factor in the association between parental 
longevity and cardiovascular risk. The improved health status associated with increased 
parental longevity may be partly due to shared environmental factors, including diet, between 
parents and their offspring. This highlights the importance of properly accounting for the 
complex role of BMI in this context. 
Study limitations 
Our study suffers from some limitations. First, parental longevity was not measured but only 
reported. This may lead to some nondifferential misclassification of parental longevity that 
should rather weaken the true underlying associations. Therefore, we may have 
underestimated the impact of parental longevity on the participants' cardiovascular risk 
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profile. Second, we have no information on parental BMI. Although this limits our capacity 
to understand the underlying pathophysiological processes, it does not decrease the 
usefulness of this simple and readily accessible piece of information (parental longevity) in 
clinical practice. Third, we have no information on smoking habits of parents. As parental and 
childhood smoking habits are closely related (Rainio et al. 2008), it is unlikely that the associations 
observed in never-smoking women are confounded by parental smoking. However, we cannot 
evaluate the impact of parental smoking on offspring's smoking status and how this might 
affect the absence of association of metabolic syndrome with parental longevity. Differences 
between men and women suggest a possible hormonal explanation for women's better profile. 
As 98.4 % of women were postmenopausal, we cannot explore the link between sex 
hormones and longevity in our study. This should be further investigated. Another limitation 
is that we cannot exclude a healthy volunteer bias. If our hypothesis that better fitness favors 
the detection of the beneficial effects of parental longevity is true, the fact that our study 
participants could be, on average, healthier than individuals from the general population, 
would lead to an overestimation of the beneficial effect of parental longevity on 
cardiovascular risk as compared to a sample devoid of healthy volunteer bias. We have not 
conducted separate analyses by former and current smoking status because of small sample 
sizes. As former smokers might have a metabolic benefit and be more health-conscious than 
current smokers, we would expect intermediate findings in former smokers. Finally, the low 
participation rate limits the external validity of our findings. Such participation rate is 
however comparable to those observed in MONICA surveys in France and Switzerland (Wolf 
et al. 2005). The magnitude of the non-participation bias is not proportional to the percentage 
of non-participants ( Galea et al. 2007) and a study on representativeness observed that people 
with risky behaviours participated in the same proportions as people without risk factors 
(Taylor et al. 2006). Moreover, in CoLaus, the age, gender and zip code distributions in 
participants were comparable to those observed in the source population (Firmann et al. 
2008). As the study was restricted to Caucasians, our findings may not apply to other ethnie 
groups. 
CONCLUSIONS 
Although each single cardiovascular risk factor was only moderately associated with parental 
longevity, the clustering of cardiovascular risk factors, as reflected by the prevalence of the 
metabolic syndrome, was strongly associated with parental longevity in women. This gender 
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difference, together with the observation that the beneficial effect of parental longevity was 
only present in never smokers, suggests that smoking may offset the benefits of having long-
lived parents. 
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Table 1: Participants' Characteristics, Overall and by Sex*. The CoLaus study, Lausanne, 
Switzerland {2003-2006}. 
Characteristic TOTAL MEN WOMEN (n=2561) (n=1163) (n=1398) 
Age (years) 63.6 ± 5.6 63.6 ± 5.5 63.6 ± 5.6 
Body mass index (kg/m2) 26.6 ± 4.6 27.4 ± 4.0 25.9 ± 4.9 
Height (cm) 167.0 ± 9.0 173.5 ± 7.1 161.6 ± 6.4 
Weight (kg) 74.5±15.1 82.7 ± 13.2 67.7 ± 13.0 
Education level (%) 
Basic 21.7 15.3 27.0 
Apprenticeship 41.0 42.5 39.8 
High school certificate 9.5 8.3 10.4 
Higher degree 14.1 15.7 12.8 
University degree 13.6 18.1 9.9 
Treatnient 
Antihypertensive treatment (%) 31.5 35.8 28.0 
Antidiabetic treatment (%) 6.9 10.6 3.8 
Lipid lowering treatment (%) 20.5 25.0 16.7 
Alcohol consumption (%) 31.8 44.6 21. l 
Current smokers (%) 21.7 24.9 19.0 
Former-smokers (%) 37.5 47.7 28.9 
Persona! history 
Acute myocardial infarction (%) 2.9 5.0 1.1 
Stroke (%) 1.8 2.3 1.4 
Diabetes (%) 10.9 16.9 6.0 
Father's history 
Acute myocardial infarction (%) 17.5 16.7 18.2 
Stroke (%) 11.l 10.5 11.6 
Diabetes (%) 7.9 8.1 7.8 
Mother' s history 
Acute myocardial infarction (%) 9.1 7.2 10.7 
Stroke (%) 11.4 9.5 13.0 
Diabetes (%) 11.5 9.8 12.8 
*Data are means ± SD, unless stated otherwise. 
15 
Table 2. Anthropometric Variables by Parental Longevity Categories. The CoLaus study, 
Lausanne, Switzerland {2003-2006}. 
Trait Mo del 0 parent 1 parent 2 parents 
Height (cm) Unadjusted 166.6 (166.1-167.0) 167.3 (166.9-167.7) 168.1 (167.3-168.9) :j: 
Model 1 166.8 (166.5-167.1) 167.2 (166.9-167.5) 167.6 (167.0-168.1) t 
Model2 166.7 (166.4-167) 167.2 (167.0-167.5) 167.8 (167.2-168.3) :j: 
Weight (kg) 
Men U11adjusted 82.8 (81.7-83.8) 82.6 (81.7-83.5) 82.4 (80.7-84.1) 
Model 1 82.7 (81.6-83.7) 82.6 (81.8-83.5) 82.6 (80.9-84.3) 
Model2 82.8 (81.9-83. 7) 82.6 (81.8-83.4) 82.3 (80.7-83.9) 
Women Unadjusted 68.7 (67.8-69.6) 67 (66.2-67.7) 65.2 (63.6-66.8) :j: 
Model 1 68.5 (67.6-69.4) 67.0 (66.3-67.8) 65.5 (64.0-67.1) :j: 
Model2 68.8 (67.9-69.6) 66.9 (66.1-67.7) 65.0 (63.5-66.6) § 
BMI (kg/m2) 
Men U11adjusted 27.6 (27.3-27.9) 27.4 (27.1-27.6) 27.2 (26.6-27.7) 
Modèl 1 27.5 (27.2-27.8) 27.4 (27.1-27.7) 27.3 (26.8-27.9) 
Wol11e11 U11adjusted 26.4 (26.1-26.8) 25.6 (25.3-25.9) 24.7 (24.1-25.3) § 
Model 1 26.4 (26.0-26.7) 25.6 (25.3-25.9) 24.8 (24.2-25.4) § 
Waist (cm) 
Men Unadjusted 99.4 (98.5-100) 99.2 (94.5-99.9) 99.1 (97.6-100.5) 
Model 1 99.3 (98.4-100.0) 99.3 (98.5-100.0) 99.3 (97.8-101.0) 
Model2 99.3 (98.5-100.2) 99.2 (98.5-100.0) 99.2 (97.7-100.6) 
Women U11adjusted 87.9 (86.7-88.7) 85.7 (85.0-86.5) 83.6 (82.1-85.1) § 
Model 1 87.7 (86.9-88.6) 85.8 (85.1-86.6) 83.9 (82.4-85.5) § 
Model2 87.7 (86.9-88.6) 85.0 (85.8-86.6) 83.9 (82.4-85.5) § 
*Data are mean (confidence interval). t: p<0.05; :j:: p<0.01 ; §: p<0.001. BMI, body mass index. 
Model 1: adjustment for age, sex, smoking status, alcohol, educational level. 
Model 2: adjustment for age, sex, smoking status, alcohol, educational Ievel and BMI (height if waist, 
weight if height) 
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Table 3. Association of Blood Pressure, Lipids, Glucose and Insulin with Parental 
Longevity Categories*. The CoLaus study, Lausanne, Switzerland {2003-2006}. 
Trait Model 0 parent 1 parent 2 parents 
SEP Unadjusted 136.7 (135.8-137.7) 135.8 (134.9-136.6) 134.8 (133.1-136.5) 
(mm Hg) Model 1 136.8 (135.9-137.8) 135.7 (134.9-136.5) 134.5 (132.9-136.1) t 
Model2 136.7 (135.8- 137.6) 135.8 (135.0-136.6) 134.8 (133 .2-136.4) 
DBP Unadjusted 81.0 (80.4-81.6) 80.7 (80.2-81.1) 80.3 (79.3-81.3) 
(mm Hg) Model 1 81.9 (81.ù-82.7) 79.5 (78.6-80.5) 80 .3 (79 .4-81.3) 
Model2 81.7 (80.8-82.59 79.7 (78.8-80.6) 80.6 (79. 7-81.5) 
pp Unadjusted 55.7 (55.0-56.5) 5.5.1 (54.5-55.7) 54.5 (53.2-55.7) 
(mm Hg) Model 1. 55.5 (54.4-56.5) 55.5 (54.4-56.7) 54.2 (53.0-55.3) t 
Model2 55.4 (54.4-56.4) 55.6 (54.4-56.7) 54.2 (53.0-55.3) t 
Cholesterol Unadjusted 5.79 (5.7-5.9) 5.79 (5.7-5.8) 5.79 (5.7-5.9) 
(mmol/L) Model 1 5.79 (5.7-5.8) 5.79 (5.7-5.8) 5.79 (5.7-5.9) 
Model2 5.79 (5.7-5.8) 5.79 (5.7-5.8) 5.79 (5.7-5.9) 
HDL Unadjusted 1.59 (1.56-1.61) 1.62 (1.60-1.64) 1.65 (1.61-1.69) + 
(mmol/L) Model 1 1.59 (1.57-1.61) 1.62 (1.60-1.64) 1.65 (1.62-1.69) + 
Model2 1.59 (1.58-l.61) 1.61 (1.60--1.63) 1.63 (l.60'-1.66) 
Triglycerides Unadjusted 1.21 ( 1.l 8-1.24) 1.18 (l.15-1.20) 1.14 (1.09-1.19) t 
(mmol/L) Model 1 1.21 (L18-l.24) 1.18 (1.15-1.20) 1.15 (l.10-1.19) + 
Modet2· 1.20 (1.17-1.23) 1.18 (1.16-1.21) 1.17 (l.13-1.22) 
Glucose Unadjusted 5.68 (5.63-5.74) 5.62 (5.57-5.67) 5.55 (5.46-5.65) t 
(mmol/L) Model 1 5.68 (5.63-5.73) 5.62 (5.58-5.67) 5.57 (5.48-5.65) 
Model2 5.66 (5.61-5.71) 5.63 (5.59-5.67) 5.60 (5.52-5.68) 
Insu lin Unadjusted 7.91 (7.66-8.16) 7.85 (7.64-8.06) 7.79 (7.38-8.22) 
(U/L) Model 1 7.89(7.65-8.13) 7.86 (7.66-8.07) 8.00 (7.45-8.26) 
Model2 7.62 (7.42-7.83) 7.77 (7.60-7.96) 7.94 (7.58-8.32) 
*Data are mean (confidence interval);t: p<0.05; +: p<0.01 ; §: p<0.001. SBP: systolic blood pressure 
; DBP: diastolic blood pressure; HDL: High Density Lipoprotein cholesterol. 
Mode! 1: adjustment for age, sex, smoking status, alcohol, educational level (antihypertensive 
medication for SBP, DBP, PP ; lipid lowering medication for triglycerides and cholesterol). 
Mode! 2: adjustment for age, sex, smoking status, alcohol, educational level and BMI (height if BMI 
or waist, weight if height) (antihypertensive medication for SBP, DBP, PP ; lipid lowering medication 
for triglycerides and cholesterol) 
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Table 3a. Association of Blood Pressure, Lipids, Glucose and Insulin with Parental 
Longevity Categories* in Never Smokers. The CoLaus study, Lausanne, Switzerland 
{2003-2006}. 
Trait Model 0 parent 1 parent 2 parents 
SBP Unadjusted 137.6 (136.l;.139.1) 136.2 (134.9-137.5) 134.9 (132.3-137.4) 
(mm Hg) Model 1 137.4 (136.0-128.8) 136.3 (135.0-137.5) 135.2 (132.8-137.6) 
· Mode12 137.2 (135.8':"138.9) 136.4 (135.2-137.7) 135.7 (133.2-138.1) 
DBP . Unadjusted 81.2 (80.4•82.l) 81.1 (80.3-81.8) 80.9 (79.5-82.3) 
(mm Hg) Model 1 81.3 (80.5-82.1) 80.7 (79.8-81.6) 81.9 (80.1-83.8) 
Model2 81.1 (80.3-81.9) 80.8 (80,0-81.7) 82.3 (80.4-84.1) 
pp Ùnadjusted 56.3 (55.2-57.5) 55 .2 (54.2-56.2) 54.0 (52.0:-55.9) 
(mm Hg) Model 1 56;1 (55.1-57.2) 55.9 (54.7-57.0) 52.6 (50.2-55.0) 
Model2 56. l (55.0-57.1) 55.9 (54,8-57.0) 52.7 (50;2-55.1) 
Cholesterol Unadjusted 5.91 (5.84-6;00) 5.89 (5.82-5.95) 5.86 (5.72-5.99) 
(mmol/L) Modell 5.92 (5.84-5.99) 5.89 (5.82-5.95) 5.86 (5.72-5.99) 
Model2 5.91 (5.84-5.99) 5.88 (5.81"'.5.95) 5.86 (5.73-6.00) 
HDL Unadjusted 1.62 (1.59.-1.66) 1.68 (1.65,..1.71) 1.74 (1.68-1.81) t 
(mmol/L) Madel 1 1.62 (1.59-1.66) 1.68 (1.65-1.71) 1.74 (1.68-1.80) t 
Model2 1.64 (1.61-1.67) 1.67 ( 1.65-1. 70) 1.71 (1.65-1.76) t 
Triglycerides Unadjusted 1.18 (1.14-1.23) 1.11 (1.08,.1.15) 1.04 (0.98-l.11) t 
(mmol/L) Model l 1.18. (1.13-1.23) 1.11 (1.09-1.15) 1.05 (0.99-1.12) t 
Model2 1.16 (1.12-1.20) 1.12 (1.09-1.16) 1.09 (l.03;.1.15) 
Glucose Unadjusted 5.60. (5.53-5.68) 5.51 (5.44-5.57) 5.40 (5.27-5.54) t 
(mmol/L) Model 1 5.59 (5.51-5.57) 5.52 (5.45-5.58) 5.44 (5.32-5.57) 
Model2 5.57 (5.49-5.64) 5.53 (5.47-5.59) 5.49 (5.37-5.62) 
Insu lin Unadjusted 7.87 (7.52-8.25) 7.67 (7.37-7.99) 7.48 (7.09-7.89) 
(U/L) Model 1 7.86 (7.51-8.22) 7.68 (7.39-7.99) 7.51 (7.13-7.91) 
Model2 7.55 (7.24-7.86) 7.67 (7.40-7.94) 7.81 (7.28-8.38) 
*Data are mean (confidence interval);t: p<0.05; ~: p<0.01 ; §: p<0.001. SBP: systolic blood pressure 
; DBP: diastolic blood pressure ; HDL : High Density Lipoprotein cholesterol. 
Mode! 1: adjustment for age, sex, smoking status, alcohol, educational level (antihypertensive 
medication for SBP, DBP, PP ; lipid lowering medication for triglycerides and cholesterol). 
Mode! 2: adjustment for age, sex, smoking status, alcohol, educational level and BMI (height if BMI 
or waist, weight if height) (antihypertensive medication for SBP, DBP, PP ; lipid lowering medication 
for triglycerides and cholesterol) 
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Table 3b. Association of Blood Pressure, Lipids, Glucose and Insulin with Parental 
Longevity Categories* in Current and Former Smokers. The CoLaus study, Lausanne, 
Switzerland {2003-2006). 
Trait Mo del 0 parent 1 parent 2 parents 
SBP Unadjusted 136.1 (134.9-137.4) 135.4 (134.2-136.5) 134.7 (132.5-136.9) 
(mm Hg) Model 1 136.4 (135.2-137.6) 135.3 (134.2-136.3) 134.1 (132.0-136.2) 
Model2 136.3 (135.1-137.5) 135.3 (134.3-136.3) 134.3 (132.2-136.4) 
DBP Unadjusted 80.8 (80.1-81.6) 80.3 (79.7-81.0) 79.9 (78.6-81.2) 
(mm Hg) Model 1 82.6 (81.0:-84.1) 78.4 (76.8-80.1) 78.8 (77.1-80.4) 
Model2 82.3 (80.7-83.8) 78.8 (77.1-80.4) 79.1 (77.5-80.7) 
pp Unadjusted 55.3 (54.4-56.2) 55.1 (54.3o.55.9) 54.8 (53.2-56.5) 
(mm Hg) Model 1 55.8 (53.9-57.6) 54.7 (52.8-56.6) 54.0 (52.1-55.9) 
Model2 55.7 (54.7-56.8) 54.7 (53.6-55.9) 54.0 (51.6:-56.4) 
Cholesterol Unadjusted 5.72 (5.65-5.79) 5.72 (5.66-5.78) 5.72 (5.60-5.84) 
(mmol/L) Model 1 5.70 (5.63-5.77) 5.73 (5.67-5.79) 5.76 (5.64-5.88) 
Model2 5.70 (5.63-5.77) 5.73 (5.67-5.79) 5.76 (5.64-5.88) 
HDL Unadjusted 1.56 (1.53-1.59) 1.57 ( 1.55-1.60) 1.59 ( 1.54-1.64) 
(mmol/L) Model 1 1.56 ( 1.54-1.58) 1.57 (1.55-1.60) 1.59 (l.55-1.64) 
Model2 1.56 (1.54-159) 1.57 (l.55-1.59) 1.58 (1.54-1.62) 
Triglycerides Unadjusted 1.2'.3 (1.20-1.28) 1.23 ( 1.19-1.26) 1.22 (1.15-1.29) 
(mmol/L) Model 1 1.23 (1.19-1.27) 1.23 (1.19-1.26) 1.23 (l.16-1.30) 
Model2 1.22 ( 1.19-1.26) 1.23 (1.20-1.27) 1.24 (l.18-1-31) 
Glucose Unadjusted 5.73 (5.66-5.81) 5.69 (5.63-5.76) 5.65 (5.52-5.78) 
(mmol/L) Model 1 5.74 (5.67-5.80) 5.70 (5.64-5.75) 5.65 (5.54-5.77) 
Model2 5.73 (5.67-5.79) 5.70 (5.64-5.75) 5.67 (5.56-5.79) 
Insu lin Unadjusted 7.93 (7.60-8.27) 7.97 (7.68-8.27) 8.01 (7.45-8.61) 
(U/L) Model 1 7.92 (7.61-8.24) 7.97 (7.70-8.25) 8.04 (7.50-8.62) 
Model 2 7.70 (7.43-7.97) 7.83 (7.59-8.07) 7.98 (7.50-8.48) 
*Data are mean (confidence interval);t: p<0.05 ; :~: p<O.O 1 ; §: p<0.001. SBP: systolic blood pressure 
; DBP: diastolic blood pressure ; HDL : High Density Lipoprotein cholesterol. 
Model 1: adjustment for age, sex, smoking status, alcohol, educational level (antihypertensive 
medication for SBP, DBP, PP ; lipid lowering medication for triglycerides and cholesterol). 
Model 2: adjustment for age, sex, smoking status, alcohol, educational level and BMI (height if BMI 
or waist, weight if height) (antihypet1ensive medication for SBP, DBP, PP ; lipid lowering medication 
for triglycerides and cholesterol) 
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Table 4. Association of Selected Cardiometabolic Variables with Parental Longevity 
Categories*. The CoLaus stud~, Lausanne, Switzerland {2003-2006}. 
Trait Model 0 parent 1 parent 2 parents 
CRP (µmol/L) Unadjusted 1.28 (1.24-1.32) 1.41 (1.35-1.47) 1.54 (1.41-1.69)§ 
Model 1 1.35 (1.30-1.39) 1.27 (l.21-1.33) 1.00 (l,08-l.31)t 
Model2 1.33 ( 1.29-1.3 7) 1.30 ( 1.25-1.36) 1.27 (1.17-1.39) 
AST (U/L) Unadjusted 28.0 (27.5-28.4) 27.3 (26.9-27.7) 26.7 (26.0-27.4):!: 
Mode! 1 28.0 (27.6-28.4) 27.3 (26.9-27.6) 27.0 (26.0-27.3):!: 
Model2 27.9 (27.5-28.3) 27.3 (27.0-27. 7) 26.8 (26.l-27.5)t 
ALT(U/L) Unadjusted 23.4 (22.9-24.0) 23.0 (22.6-23.5) 22. 7 (21.8-23 .6) 
Madell 23.4 (22.9-23.9) 23.1 (22.6-23.5) 23.0 (21.9-23.6) 
Madel2 23.2 (22.8-23.7) 23.2 (22;7-23.6) 23 .1 (22.3-23 .9) 
GGT(U/L) Unadjusted 24.6 (23.8-25.4) 23.7 (23.1-24.4) 22.9 (21.8-24.2) t 
Madel 1 24.7 (24.0-25.4) 23.7 (23.1-24.3) 23 .0 (21.8-24.0):!: 
Model2 24.5 (23.8-25.2) 23.8 (23.3-24.4) 23.2 (22.1-24.4) 
Adiponectin Unadjusted 7.69 (7.54-7.84) 8.32 (8.09-8.55) 8.00 (8.52-9.50)§ 
(mg/mL) Madel 1 7.87 (7.73-8.02) 7.90 (7.69-8.12) 7.93 (7.51-8.38) 
Model2 7.91 (7. 76-8.01) 7.85 (7.64-8.05) 7.78 (7.37-8.22) 
Lepti,-i Men Unadjusted 7.34 (6.90-7.81) 7.47 (7.09-7.87) 7.60 (6.85-8.43) 
(ng/mL) Model 1 7.31 (6,88-7.78) 7.48 (7.04-7.96) 7.66 (6.90-8.50) 
Model2 7.29 (6.93-7.66) 7.50 (7.19-7.83) 7.73 (7.10-8.42) 
Leptin Women Unadjusted 15.4 (14.6-16.3) 14.2 (13.5-14.8) 13.0 (11.9-14.3):!: 
(ng/mL) Model 1 15.3 (14.5-16.1) 14.3 (13.6-14.9) 13.3 (12.l-14.6)t 
Model2 14.8 (14.1-15.4) 14.6 (14.1-15.2) 14.5 (13.5-15.6) 
Homocysteine Unadjusted 10.5 (10.4-1o.7) 10.5 (10.4-10.7) 10.6 (10.3-10.8) 
(µmol/L) Mode! 1 10.6 ( 10.4-1o.7) 10.5 (10.4-10.6 10.0 (10.2-10.7) 
Model2 10.5 (10.4-10.7) 10.5 (10.4-10.6) 10.5 (10.2-10.8) 
Urie acid Unadjusted 332 (328-336) 327 (324-331) 323 (315-330) 
(µmol/L) Mode! 1 333 (329-337) 327 (324-330) 321 (314-328):!: 
Model2 331 (328-335) 328 (325-331) 324 (318-331) 
*Data are mean (confidence interval). i·: p<0.05; :!:: p<0.01 ; §: p<0.001. CRP, C-Reactive Protein; 
AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; GGT, Gamma Glutamyl 
Transferase; ALKP, Alkaline Phosphatase. 
Mode! 1: adjustment for age, sex, smoking status, alcohol, educational level. 
Mode! 2: adjustment for age, sex, smoking status, alcohol, educational level and BMI (height if BMI 
or waist, weight if height). 
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Table 4a. Association of Selected Cardiometabolic Variables with Parental Longevity 
Categories* in Never Smokers. The CoLaus study, Lausanne, Switzerland (2003-2006). 
Trait Model 0 parent 1 parent 2 parents 
CRP (µmol/L) Unadjusted 1.75 (1.61-1.91) 1.56 (1.45-1.68) 1.40 (1.21-1.62) t 
Modell 1.74 (1.60-1.90) 1.57 ( 1.46-1.69) 1.42 (1.23-1.64) t 
Model2 1.66 (1.54-1.79) 1.62 (1.52-1.73) 1.58 (1.38-1.79) 
AST (U/L) Unadjusted 27.5 (27.0-28.1) 27.1 (26.6-27.6) 26.7 (25.8-27.6) t 
Model 1 27.8 (27.2-28.4) 27.1 (26.6-27.6) 26.6 (25.7-27.6) 
Model2 27.5 (26.9-28.1) 27.1 (26.7-27.6) 26.8 (25.9-27 .8) 
ALT (U/L) Unadjusted 23 .3 (22.6-24.1) 22.5 (21.8-23.1) 21.7 (20.5-22.9) t 
Model 1 23.3 (22.6-24.1) 22.5 (21.9-23.1) 21.7 (20.5-22.9) t 
Model2 23 .1 (22.4-23 .9) 22.6 (22.0-23.2) 22.l (21.0-23.3) 
GGT(U/L) Unadjusted 23.2 (22.1-24.3) 22.2 (21.3-23.1) 21.2 (19.7-23.0) 
ModelJ 23.2 (22.2-24.2) 22.2 (21.4-23.1) 21.3 (19.8-22.9) 
Model2 22.9 (21.9-24.0) 22.3 (21.5-23 .2) 21.8 (20.3-23 .5) 
Adipol1ectin Unadjusted 9.21 (8.71-9.73) 9.69 (9.23-10.17) 10.20 (9.26-11.21) 
(mg/mL) Model 1 9.21 (8.74-9.71) 9.68 (9.25-10.13) 10.16 (9.29~11.13) 
Model2 9.34 (8.97-9.72) 9.61 (9.20-10.03) 9.89 (9.05-10.80) 
LeptinMen Unadjusted 6.74 (6.04-7.52) 7.07 (6.43-7.77) 7.41 (6.15-9.92) 
(ng/mL) Model 1 6.73 (6.02~7.52) 7.07 (6.44-7.77) 7.39 (6.12-8.92) 
Model2 6.69 (6.09-7.35) 7.10 (6.46-7.80) 7.54 (6.44-8.82) 
Leptin Women Unadjusted 16.61(15.46-17.85)14.73 (13.85-15.67) 13.05 (11.55-14.75) + 
(ng/mL) Model 1 16.54 (15.40-17.78) 14.81 (13.92-15.75) 13.25 (11.72-14.99) + 
Model2 15.83 (14.94-16.77) 15.24 (14.51-16.00) 14.66 (13.27-16.19) 
Homocysteine Unadjusted 10.3 (10.1-10.5) 10.1 (10.0-10.3) 10.0 (9.7-10.4) 
(µmol/L) Model 1 10.2 (10.0-10.5) 10.1 (10.0-10.3) 10.0 (9.7-10.4) 
Model2 10.2 (10.0-10.4) 10.1 (10.0-10.3) 10.1 (9.7-10.5) 
Urie acid Unadjusted 320 (314-326) 314 (308-319) 307 (296-318) 
(µmol/L) Model 1 320 (314-326) 314 (309-319) 308 (298-318) 
Model2 318 (312-323) 315(311-320) 313 (304-323) 
*Data are mean (confidence interval). t: p<0.05; :j:: p<0.01 ; §: p<0.001. CRP, C-Reactive Protein; 
AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase ; GGT, Gamma Glutamyl 
Transferase; ALKP, Alkaline Phosphatase. 
Mode! l: adjustment for age, sex, smoking status, alcohol, educational level. 
Mode! 2: adjustment for age, sex, smoking status, alcohol, educational level and BMI (height if BMI 
or waist, weight if height). 
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Table 4b. Association of Selected Cardiometabolic Variables with Parental Longevity 
Categories* in Current and Former Smokers. The CoLaus study, Lausanne, Switzerland (2003-
2006. 
Trait Model 0 parent 1 parent 2 parents 
CRP (µmol/L) Unadjusted 1.75 (1.63-1.88) 1.63 ( 1.53-1. 73) 1.52 (1.34-1.71) 
Madel 1 1.74 (1.62-1.87) 1.64 (1.54-1.74) 1.54 (1.36-1.74) 
Model2 1.72 (l.61-1.84) 1.65 (1.55-1.75) 1.5 8 ( 1.40-1. 77) 
AST (U/L) Unadjusted 27.9 (27.3-28.5) 27.4 (26.9-28.0) 26.6 (25.7-27.7) t 
Madel 1 28.3 (27.7-28.9) 27.4 (26.9-27.9) 26.6 (25.6-27.5) t 
Model2 28.2 (27.6-28.9) 27.4 (26.9-.27.9) 26.7 (25.7-27.6) t 
ALT(U/L) Urtadjusted 23.5 (22.S:-24.2) 23.4 (22.8-24.1) 23A (22.2-24. 7) 
Model 1 23.4 (22.8M24.l) 23.5 (22.9-24.1) 23.5 (22.3-24.7) 
Model2 23.3 (22.7-24.0) 23.5 (23.0-24.1) 23 .8 (22.6-25 .0) 
GGT(U/L) Unadjusted 25.6 (24.6-26.8) 24.9 (24.0-25.9) 24.2 (22.6-26.1) 
Model 1 25.7 (24.8-26.8) 24.9 (24.1-25. 7) 24.0 (22.6-25.7) 
Model2 25.6 (24.7-26.6) 24.9 (24.2-25.8) 24.3 (22.8-25.9) 
Adiponectin Unadjusted 8.35 (7.98-8.74) 8.10 (7.79-8.43) 7.94 (7.34-8.60) 
(mg/mL) Model 1 8.43 (8.08-8.80) 8.17 (7.87-8.48) 7.91 (7.34-8.52) 
Model2 8.50 (8.16-8.86) 8.10 (7.81~8.40) 7.84 (7.29-8.43) 
Leptin Men Unadjusted 7.58 (7.05-8.15) 7.62 (7.16-8.12) 7.66 (6.76-8.68) 
(ng/mL) Madel 1 7.56 (7.02-8.13) 7.64 (7.18-8.14) 7.73 (6.82-8.77) 
Model2 7.53 (7.10-7.98) 7.66 (7.29-8.05) 7.80 (7.06-8.63) 
Leptin Women Unadjusted 14.20 (13.14-15.35) 13.58 (12.67-14.55) 12.98 (11.31-14.91) 
(ng/mL) Model 1 14.07 (13.02-15.20) 13.67 (12.77-14.65) 13.29 (11.57-15.27) 
Model2 13.70 (12.90~14.55) 13.94 (13.22-14.70) 14.18 (12.74-15.79) 
Homocysteine Unadjusted 10.7 (10.5-10.9) 10.8 (10.6-11.0) 10.9 (10.6-11.4) 
(µmol/L) Mode! 1 10.8 (10.6-11.0) 10.8 (10.6-11.0) 10.8 (10.4-11.2) 
Model2 10.8 (10.6-11.0) 10.8 (10.6-11.0) 10.8 (10.4-11.2) 
Urie acid Unadjusted 340 (334-346) 337 (332-342) 334 (324-344) 
(µmol/L) Madel 1 341 (336-346) 336 (331-340) 330 (321-339) 
Model2 340 (336-345) 336 (332-341) 332 (324-341) 
*Data are mean (confidence interval). t: p<0.05; ~: p<0.01 ; §: p<0.001. CRP, C-Reactive Protein; 
AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase ; GGT, Gamma Glutamyl 
Transferase; ALKP, Alkaline Phosphatase. 
Mode! 1: adjustment for age, sex, smoking status, alcohol, educational level. 
Model 2: adjustment for age, sex, smoking status, alcohol, educational level and BMI (height 
if BMI or waist, weight if height). 
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Table 5. Framingham Risk Score by Parental Longevity Categories, overall and by 
smoking status. * The CoLaus study, Lausanne, Switzerland (2003-2006). 
Framingham Risk Score 0 parent 
Men 11.74 (11.27-12.20) 
(n=580) 
Women 3.11 (2.91-3.30) 
(n==718) 
Non-smoking men 9.33 (8.44-10.23) 
(n=l63) 
Non'.'smoking womeh 2. 7l (2.46-2.95) . 
(h=370) 
Smoking men 12.67 (ll.85~13.50) 
(former and current) (n=417) 
Smoking women 3.53 (3.04-4.03) 
(former and current) (n=348) 
*Data are mean (confidence interval) 
t: p<0.05 
1 parent 2 parents 
11.75 (11.26-12.24) 11.00 (10.58-11.44) 
(n=453) (n=130) 
3.12 (2.95-3.29) 2.51 (2.38-2.64) t 
(n=538) (n=l42) 
9.31 (8.22-10.40) 8.57 (6.90-10.24) 
(n=117) (n=38) 
2.60 (2.37-2.83) 1.99 (1.62-2.36) t 
(n=280) (n=79) 
12.60 (1 l.58-13.61) 12.02 (10.41-13.63) 
(n=336) (n=92) 
3.68 (3.16-4.20) 3.16 (2.43-3.89) 
(n=258) (n=63) 
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Figure legends. 
Figure 1. Relationship between Anthropometric Variables and Categories of Parental 
Longevity, by Sex. The CoLaus study, Lausanne, Switzerland (2003-2006). 
Upper panels: BMI. Middle panels: Weight. Lower panels: Waist circumference. 
Figure 2. Age-adjusted Prevalence of the Metabolic Syndrome by Categories of Parental 
Longevity, Smoking Status and Sex. The CoLaus study, Lausanne, Switzerland (2003-
2006). 
Numbers on top of bars represent sample sizes. 0, 1 and 2 labels on the x axis represent the 
number of long-lived parents. Age-adjustment was done using direct standardization in Stata. 
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